News | July 05, 2012

Avinger Completes Enrollment in Trial of Forward-Looking OCT, CTO-Crossing Catheter

July 5, 2012 — Avinger Inc., a medical device manufacturer of multifunctional catheters for treating patients with peripheral artery disease (PAD), announced in June that it has successfully completed enrollment in its CONNECT II global clinical trial. PAD is a silent epidemic that affects 8 to 12 million adults in the United States and 30 million globally, and is the leading cause of amputation in patients over 50. A study published in the January 2012 issue of the American Heart Association journal Circulation claims that PAD is an unsung “pandemic” that afflicts even more women than men.

CONNECT II is a global clinical study that evaluated the safety and efficacy of Ocelot, the first interventional chronic total occlusion- (CTO) crossing catheter to use real-time intravascular imaging technology called optical coherence tomography (OCT). It allows physicians to cross, see and navigate inside totally blocked arteries in the legs of patients suffering from PAD.

“We are pleased to reach this significant milestone ahead of schedule and already see promising preliminary data collected,” said Avinger CEO and founder John B. Simpson. “We appreciate the patient participation and dedicated efforts of our employees, physician investigators and their research staffs. Together, we are now one step closer to bringing the Ocelot technology to patients who need it most.”

The company will present CONNECT II aggregate results at the VIVA conference in October 2012, file a 510K with the U.S. Food and Drug Administration (FDA) later this summer, and expects to receive 510K clearance in late 2012. In order to ensure Ocelot is available for use at U.S. CONNECT II sites during the 510K review period, Avinger has also requested FDA approval of an additional 125 patients to be enrolled and treated in a continued-access cohort.

CONNECT II is a prospective, multicenter, nonrandomized global clinical study that evaluated 100 PAD patients with femoropopliteal CTO lesions at 15 hospital and clinic sites, including two in the European Union, where Ocelot received CE mark in 2011. As part of the trial, an independent group of physicians are reviewing the angiographic results to determine Ocelot’s safety and efficacy.

For more information: www.avinger.com

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init